Investing In China: Views from Windhover's PharmAsia Summit

A recap of the first annual PharmAsia Summit, outlining current views on the opportunities and risks associated with investing in China.

It's common wisdom within the halls of Big Pharma to look East--especially to China--for future revenue growth as increasing regulatory oversight and reimbursement hurdles in the US and Europe create commercial challenges. With a booming economy that slowed but didn't stall during the most recent global recession, China has 1.3 billion people who are increasingly able to afford new medicines, even as that country's government crafts health care legislation that would mandate universal coverage by 2020. Changes in patent law to closely mirror Western standards make doing business in China considerably less risky than just a few years ago, while the significantly lower labor costs offer the opportunity of arbitrage.

For all these potential benefits, however, venture capitalists haven't rushed to invest in China-based start-ups. Nor have biotechs necessarily thought...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from China

China Signals Restarting IPOs For Unprofitable Biotechs

 

The China Securities Regulatory Commission has proposed a new “growth tier” for the STAR Market of the Shanghai Stock Exchange, to reinstate the market’s listing standards for unprofitable firms.

Innovent Builds Metabolic Pipeline While Retaining Oncology Backbone

 
• By 

Innovent presented data on multiple pipeline assets at ASCO, including promising OS results for its first-in-class anti-PD-1/IL-2α-bias bispecific. The Chinese firm is also continuing to build out its metabolic disease portfolio and consider its partnering strategies, its CEO tells Scrip.

Henlius CEO Details PD-L1 ADC’s Path To 1L Mono/Combo Therapy

 

Henlius is investigating the optimum dose for its PD-L1-targeting antibody-drug conjugate HLX43 to support potential first-line use, its CEO explains to Scrip.

AstraZeneca Taps Into China’s R&D Engine With CSPC Alliance

 

After in-licensing a cardiovascular candidate last year, AstraZeneca has signed a strategic drug discovery alliance, which could generate billions of dollars in payments to the Chinese firm.

More from Focus On Asia

Henlius CEO Details PD-L1 ADC’s Path To 1L Mono/Combo Therapy

 

Henlius is investigating the optimum dose for its PD-L1-targeting antibody-drug conjugate HLX43 to support potential first-line use, its CEO explains to Scrip.

Big Top-Level Shifts At Sun: Ganorkar Is MD, Ex-Takeda Exec To Helm US Business

 

Sun’s founder hands top job to company longtimer Kirti Ganorkar as the firm implements a “structured and forward-looking” succession plan, while Richard Ascroft will lead the Indian drugmaker’s North America business.

AstraZeneca Taps Into China’s R&D Engine With CSPC Alliance

 

After in-licensing a cardiovascular candidate last year, AstraZeneca has signed a strategic drug discovery alliance, which could generate billions of dollars in payments to the Chinese firm.